tiprankstipranks
Trending News
More News >
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Compare
812 Followers
See the Price Targets and Ratings of:

RARE Analyst Ratings

Strong Buy
15Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$87.87
▲(138.07%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $87.87 with a high forecast of $136.00 and a low forecast of $39.00. The average price target represents a 138.07% change from the last price of $36.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","137":"$137","58.25":"$58.3","84.5":"$84.5","110.75":"$110.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$87.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$39.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,58.25,84.5,110.75,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.97,46.433846153846154,53.89769230769231,61.36153846153846,68.82538461538462,76.28923076923077,83.75307692307692,91.21692307692308,98.68076923076923,106.14461538461538,113.60846153846154,121.07230769230769,128.53615384615384,{"y":136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.97,42.73153846153846,46.49307692307692,50.254615384615384,54.01615384615385,57.777692307692305,61.53923076923077,65.30076923076923,69.0623076923077,72.82384615384615,76.58538461538461,80.34692307692308,84.10846153846154,{"y":87.87,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.97,38.972307692307695,38.97461538461538,38.97692307692308,38.97923076923077,38.98153846153846,38.98384615384615,38.98615384615385,38.988461538461536,38.99076923076923,38.99307692307692,38.995384615384616,38.997692307692304,{"y":39,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.3,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.14,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$136.00Average Price Target$87.87Lowest Price Target$39.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on RARE
TipRanks AITipRanks
Not Ranked
TipRanks
$35
Hold
-5.17%
Downside
Reiterated
06/03/25
The overall stock score of 46 reflects persistent financial challenges, notably poor profitability and cash flow issues, despite promising revenue growth and clinical advancements. Technical indicators suggest a bearish momentum, and valuation metrics are unattractive. However, positive aspects from the earnings call, including revenue growth and strategic milestones, provide some balance to the otherwise cautious outlook.
William Blair Analyst forecast on RARE
Matt PhippsWilliam Blair
William Blair
$65
Buy
76.10%
Upside
Initiated
05/31/25
Ultragenyx Pharmaceutical (RARE) Receives a New Rating from William Blair
RBC Capital Analyst forecast on RARE
Luca IssiRBC Capital
RBC Capital
$77
Buy
108.62%
Upside
Reiterated
05/30/25
RBC Capital Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
J.P. Morgan Analyst forecast on RARE
Anupam RamaJ.P. Morgan
J.P. Morgan
$117$116
Buy
214.28%
Upside
Reiterated
05/23/25
J.P. Morgan Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Bank of America Securities Analyst forecast on RARE
Tazeen AhmadBank of America Securities
Bank of America Securities
$80
Buy
116.74%
Upside
Reiterated
05/14/25
Bank of America Securities Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Morgan Stanley Analyst forecast on RARE
Maxwell SkorMorgan Stanley
Morgan Stanley
$64$65
Buy
76.10%
Upside
Reiterated
05/08/25
Optimistic Buy Rating for Ultragenyx: Strategic Developments and Favorable Regulatory Landscape Drive Growth Prospects
Truist Financial Analyst forecast on RARE
Joon LeeTruist Financial
Truist Financial
$140$100
Buy
170.93%
Upside
Reiterated
05/07/25
Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Leerink Partners Analyst forecast on RARE
Joseph SchwartzLeerink Partners
Leerink Partners
$90
Buy
143.84%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical: Promising Growth and Strategic Milestones Reinforce Buy Rating
TD Cowen Analyst forecast on RARE
Yaron WerberTD Cowen
TD Cowen
$86
Buy
133.00%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating
Evercore ISI Analyst forecast on RARE
Liisa BaykoEvercore ISI
Evercore ISI
$70
Buy
89.65%
Upside
Reiterated
05/07/25
Evercore ISI Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Citi
$110
Buy
198.02%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point
Wedbush
$39
Hold
5.66%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical (RARE) Receives a Hold from Wedbush
Barclays Analyst forecast on RARE
Gena WangBarclays
Barclays
$81
Buy
119.45%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Barclays
Canaccord Genuity Analyst forecast on RARE
Whitney IjemCanaccord Genuity
Canaccord Genuity
$136
Buy
268.46%
Upside
Reiterated
05/06/25
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand
Wells Fargo Analyst forecast on RARE
Tiago FauthWells Fargo
Wells Fargo
$88
Buy
138.42%
Upside
Reiterated
05/06/25
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Wells Fargo
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on RARE
TipRanks AITipRanks
Not Ranked
TipRanks
$35
Hold
-5.17%
Downside
Reiterated
06/03/25
The overall stock score of 46 reflects persistent financial challenges, notably poor profitability and cash flow issues, despite promising revenue growth and clinical advancements. Technical indicators suggest a bearish momentum, and valuation metrics are unattractive. However, positive aspects from the earnings call, including revenue growth and strategic milestones, provide some balance to the otherwise cautious outlook.
William Blair Analyst forecast on RARE
Matt PhippsWilliam Blair
William Blair
$65
Buy
76.10%
Upside
Initiated
05/31/25
Ultragenyx Pharmaceutical (RARE) Receives a New Rating from William Blair
RBC Capital Analyst forecast on RARE
Luca IssiRBC Capital
RBC Capital
$77
Buy
108.62%
Upside
Reiterated
05/30/25
RBC Capital Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
J.P. Morgan Analyst forecast on RARE
Anupam RamaJ.P. Morgan
J.P. Morgan
$117$116
Buy
214.28%
Upside
Reiterated
05/23/25
J.P. Morgan Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Bank of America Securities Analyst forecast on RARE
Tazeen AhmadBank of America Securities
Bank of America Securities
$80
Buy
116.74%
Upside
Reiterated
05/14/25
Bank of America Securities Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Morgan Stanley Analyst forecast on RARE
Maxwell SkorMorgan Stanley
Morgan Stanley
$64$65
Buy
76.10%
Upside
Reiterated
05/08/25
Optimistic Buy Rating for Ultragenyx: Strategic Developments and Favorable Regulatory Landscape Drive Growth Prospects
Truist Financial Analyst forecast on RARE
Joon LeeTruist Financial
Truist Financial
$140$100
Buy
170.93%
Upside
Reiterated
05/07/25
Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Leerink Partners Analyst forecast on RARE
Joseph SchwartzLeerink Partners
Leerink Partners
$90
Buy
143.84%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical: Promising Growth and Strategic Milestones Reinforce Buy Rating
TD Cowen Analyst forecast on RARE
Yaron WerberTD Cowen
TD Cowen
$86
Buy
133.00%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating
Evercore ISI Analyst forecast on RARE
Liisa BaykoEvercore ISI
Evercore ISI
$70
Buy
89.65%
Upside
Reiterated
05/07/25
Evercore ISI Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Citi
$110
Buy
198.02%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point
Wedbush
$39
Hold
5.66%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical (RARE) Receives a Hold from Wedbush
Barclays Analyst forecast on RARE
Gena WangBarclays
Barclays
$81
Buy
119.45%
Upside
Reiterated
05/07/25
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Barclays
Canaccord Genuity Analyst forecast on RARE
Whitney IjemCanaccord Genuity
Canaccord Genuity
$136
Buy
268.46%
Upside
Reiterated
05/06/25
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand
Wells Fargo Analyst forecast on RARE
Tiago FauthWells Fargo
Wells Fargo
$88
Buy
138.42%
Upside
Reiterated
05/06/25
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Wells Fargo
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

1 Month
xxx
Success Rate
12/18 ratings generated profit
67%
Average Return
+4.79%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.79% per trade.
3 Months
xxx
Success Rate
11/18 ratings generated profit
61%
Average Return
+2.37%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +2.37% per trade.
1 Year
Joon LeeTruist Financial
Success Rate
9/18 ratings generated profit
50%
Average Return
+9.75%
reiterated a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +9.75% per trade.
2 Years
xxx
Success Rate
11/26 ratings generated profit
42%
Average Return
+15.77%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.31% of your transactions generating a profit, with an average return of +15.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
22
28
28
24
24
Buy
12
6
4
4
1
Hold
2
2
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
36
34
30
27
In the current month, RARE has received 25 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 87.87.
Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$1.30 with a range of -$1.50 to -$1.04. The previous quarter’s EPS was -$1.57. RARE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.
Next quarter’s earnings estimate for RARE is -$1.30 with a range of -$1.50 to -$1.04. The previous quarter’s EPS was -$1.57. RARE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $162.50M with a range of $155.59M to $174.00M. The previous quarter’s sales results were $139.29M. RARE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.
Next quarter’s sales forecast for RARE is $162.50M with a range of $155.59M to $174.00M. The previous quarter’s sales results were $139.29M. RARE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 87.87.
    What is RARE’s upside potential, based on the analysts’ average price target?
    Ultragenyx Pharmaceutical has 138.07% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RARE a Buy, Sell or Hold?
          Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ultragenyx Pharmaceutical’s price target?
            The average price target for Ultragenyx Pharmaceutical is 87.87. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $136.00 ,the lowest forecast is $39.00. The average price target represents 138.07% Increase from the current price of $36.91.
              What do analysts say about Ultragenyx Pharmaceutical?
              Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of RARE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis